{"disease":{"id":"lymphoproliferative-disorders","name":"lymphoproliferative disorders"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05898789","title":"Virtual Rehabilitation for Cancer Survivors","phase":"NA","overall_status":"RECRUITING","enrollment_count":388,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT02579967","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":354,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03922724","title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":330,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07445984","title":"Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)","phase":"NA","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Azienda Ospedaliero-Universitaria di Parma","has_results":false},{"nct_id":"NCT06727383","title":"CAR-NK Cells Production and Expansion From Patients With Lympho or Myeloproliferative Disorders and From Healthy Donors","phase":"NA","overall_status":"UNKNOWN","enrollment_count":140,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT03744676","title":"A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Juno Therapeutics, a Subsidiary of Celgene","has_results":true},{"nct_id":"NCT06271252","title":"A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":81,"lead_sponsor_name":"OriCell Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT00068146","title":"Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03663933","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":71,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05155215","title":"Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"Beijing Immunochina Medical Science & Technology Co., Ltd.","has_results":false},{"nct_id":"NCT04339777","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03397706","title":"Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Viracta Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03373019","title":"Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":63,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07133763","title":"Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"The Affiliated Hospital of Xuzhou Medical University","has_results":false},{"nct_id":"NCT03602157","title":"Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03258567","title":"Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02690545","title":"Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":38,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06042400","title":"Trial of Written Exposure for Metastatic Cancer Patients (EASE)","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"University of Colorado, Boulder","has_results":false},{"nct_id":"NCT04309084","title":"Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":29,"lead_sponsor_name":"Celularity Incorporated","has_results":false},{"nct_id":"NCT00345345","title":"Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":true},{"nct_id":"NCT05803616","title":"Liquid Biopsy to Enable Diagnostics and Monitoring for Immune-mediated Lymphoproliferative Disorders","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"University Hospital, Geneva","has_results":false},{"nct_id":"NCT07450391","title":"EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Daihong Liu","has_results":false},{"nct_id":"NCT02973113","title":"Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT03601819","title":"Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT03939585","title":"Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Leland Metheny","has_results":false},{"nct_id":"NCT02822495","title":"Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Atara Biotherapeutics","has_results":false}],"total":26},"guidelines":[],"source":"Drug Landscape verified database"}